network member

Massachusetts

About Network Member

Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Cancer areas:Breast

Fred & Pamela Buffett Cancer Center

New York University Cancer Institute

Orlando Health Cancer Institute

Parkview Research Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

Tufts Medical Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Arizona Cancer Center

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Michigan Health-West

University of Michigan Rogel Cancer Center

University of Virginia Cancer Center

University of Wisconsin Carbone Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

MD Anderson Cancer Center

Novant Health Oncology Specialists

Providence Cancer Institute

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University

UC San Francisco

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Columbia University Irving Medical Center

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

The Ohio State University

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Weill Cornell Medicine

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Currently Enrolling

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Angela DeMichele

Cancer areas:Breast

Dana-Farber Cancer Institute

Fred Hutchinson Cancer Research Center

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Mayo Clinic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

University of Alabama at Birmingham Comprehensive Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Michael B. Atkins

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Cleveland Clinic Cancer Center

Columbia University Irving Medical Center

Fox Chase Cancer Center

Georgetown Lombardi Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Enrollment Closed

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

UPMC Hillman Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov